03:57 PM EST - Isotechnika Pharma Inc. : said the U.S. Food and Drug Administration (FDA) has cancelled the Advisory Committee review of partner, Lux Biosciences', new drug application for voclosporin on June 28. The meeting was originally planned to provide a forum for FDA Advisors to discuss the data included in Lux's NDA for voclosporin in the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye. The FDA will continue its priority review of the NDA with the PDUFA date of August 3. Isotechnika Pharma Inc.
shares T.ISA are trading down $0.16 at $0.25.
